Noema Pharma is conducting a clinical trial to evaluate the effect of basimglurant for the management of pain in patients with trigeminal neuralgia. Is this clinical trial right for you?
Learn more about the Libra Study©
Presenters: Robert Lasser, MD, MBA, Chief Medical Officer at Noema Pharma, and Robert Silva, PhD, Vice President of Clinical Science at Noema Pharma
Dr. Rob Lasser is a seasoned biopharma executive with over 25 years of experience in the CNS space, spanning clinical practice, academic research, large pharma and biotech. He currently serves as the Chief Medical Officer of Noema Pharma with a focus on developing new therapeutics for trigeminal neuralgia. Most recently, he held an executive role at Sage Therapeutics, where he led the development of zuranolone (ZURZUVAE®) in depressive disorders. Before that, he was the CMO at MedDay Pharma. Prior to joining MedDay, he was the Head of Neurodegenerative disorders at Roche, where he oversaw the Phase 2 and 3 programs for gantenerumab through 2017. Earlier in his career, Dr. Lasser held various roles at pharmaceutical companies, including managing the medical launch and lifecycle of lisdexamfetamine (VYVANSE®) at Shire, the first medicine for treating Binge Eating Disorder, the launch of the first long-acting injectable atypical antipsychotic RISPERDAL CONSTA® at Johnson & Johnson, and developing iloperidone (FANAPT®) at Novartis in the late 1990’s. Dr. Lasser completed his Geriatric Psychiatry fellowship at the National Institute of Mental Health, and his residency in psychiatry at McLean Hospital. He obtained an M.B.A from the University of Pennsylvania Wharton School of Business, a M.D. from Boston University School of Medicine, and a B.A. in Biochemistry from Dartmouth College.
Rob Silva received his PhD in Neuroscience from the City University of New York and is a seasoned clinical-stage pharmaceutical development leader with over 20 years of industry experience. He completed a post-doctoral fellowship at Columbia University College of Physicians and Surgeons, where he received a Michael J. Fox Foundation Award in support of his work elucidating the underlying mechanisms of apoptotic cell death in Parkinson’s disease. Prior to joining Noema as Vice-President, Clinical Science, he held leadership positions at Merck, Dainippon-Sumitomo Pharma, Sunovion Pharmaceuticals, Ipsen Biosciences, UCB, and Mind Medicine, Inc. where he led multiple global development programs primarily in the areas of neurology/psychiatry culminating in several successful US and global marketing authorizations targeting difficult-to-treat conditions.
The Facial Pain Association (FPA) is enthusiastic about medical research and encourages those with neuropathic facial pain, including trigeminal neuralgia, and related healthcare conditions to consider participation. It is important to note, however, that the FPA is not offering, nor is it qualified to offer, a scientific or medical endorsement of any Institutional Review Board (IRB) approved patient study. An IRB is a committee established to review and approve research involving human subjects. The purpose of the IRB is to ensure that all human subject research is conducted in accordance with all federal, institutional, and ethical guidelines. All studies and trials listed have IRB or Ethics Committee approval where relevant. The study’s safety and scientific validity is the sole responsibility of the study sponsors and investigators. Patients should use the contact information provided to contact the research organization for more information.
Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your healthcare provider. Although study sponsors may donate to the FPA, or support the FPA through advertising or corporate sponsorship, such support does not influence or guide our decision about the studies we identify.
Noema Pharma is a sponsor of the Facial Pain Association.
